{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:41:21Z","timestamp":1781134881791,"version":"3.54.1"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"Introduction<\/jats:title>There is no consensus about the standardized uptake value maximum (SUV<sub>max<\/sub>) cut-off value to characterize pleural thickening worldwide. Sometimes, this causes unnecessary invasive diagnostic procedures. Our first aim is to determine a cut-off value for SUV<sub>max<\/sub>. Secondly, we try to answer the following question: If we use this cut-off value together with morphological parameters, can we differentiate benign thickening from malignant pleural mesothelioma (MPM) more accurately?<\/jats:p><\/jats:sec>Material and methods<\/jats:title>Thirty-seven patients who underwent 2-deoxy-2-fluoro-D-glucose ([18F]FDG) positron emission tomography\/computed tomography (PET\/CT) before pleural biopsy were included the study. All of patients had histopathologically proven primary pleural disease. Their [18F]FDG-PET\/CT imaging reports were re-assessed. If a patient\u2019s SUVmax or size of the thickening was not mentioned in the report, we calculated it with their [18F]FDG-PET\/CT.<\/jats:p><\/jats:sec>Results<\/jats:title>Age, pleural effusion, size, and SUV<sub>max<\/sub> were found to have a relationship with MPM. We found the size > 14 mm, and SUV<sub>max<\/sub> > 4.0 as cut-off values for MPM. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for size > 14 mm were found to be 86.4%, 85.2%, 82.6%, 88.5%, respectively. For SUV<sub>max<\/sub> > 4.0, sensitivity, specificity, PPV, NPV were 90.9%, 87.0%, 85.1%, 92.2%, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>If a patient has SUV<sub>max<\/sub> > 4.0 and\/or size > 14 mm, the risk of MPM is high. These patients should undergo biopsy. If a patient\u2019s SUV<sub>max<\/sub> < 4.0, size < 14 mm and does not have pleural effusion, he\/she has low risk for MPM. These patients can undergo the follow-up. If a patient\u2019s SUV<sub>max<\/sub> < 4, size < 14, and has pleural effusion the MPM risk is approximately 4%. These patients can undergo biopsy\/cytology\/follow-up. Novel studies are needed for these patients.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms\/111529","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:11:14Z","timestamp":1616544674000},"page":"385-391","source":"Crossref","is-referenced-by-count":2,"title":["How can we use positron emission tomography\/\ncomputed tomography more accurately for characterization of asbestos-related pleural thickening?"],"prefix":"10.5114","volume":"19","author":[{"given":"F. Selcuk","family":"Simsek","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Pamukkale University, Denizli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muharrem","family":"Cakmak","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Faculty of Medicine, Firat University, Elazig, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Kuslu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Antalya Education and Research Hospital, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansel","family":"Balci","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Faculty of Medicine, Firat University, Elazig, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdal","family":"In","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Faculty of Medicine, Firat University, Elazig, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ozercan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Firat University, Elazig, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Narin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Elazig Medical Park Hospital, Elazig, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2021,3,24]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-111529-88402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-111529-88402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T13:32:22Z","timestamp":1678973542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/How-can-we-use-positron-emission-tomography-ncomputed-tomography-more-accurately,111529,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"alternative-id":["111529"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/111529","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]}}}